AviaraDx confirms that combination of two molecular biomarkers improves prediction of disease recurrence in early stage breast cancer patients

Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment

Study Links HOXB13 & IL17BR with Estrogen Signaling in Breast Cancer

AviaraDx presents at 2007 BIOCOM Investor Conference

CONNECT Announces Finalists for 20th Annual Most Innovative New Product Awards

AviaraDx Announces CAP Accreditation of Its Laboratory Operations

Researchers from Sweden demonstrate H:I can predict the benefit of endocrine therapy in breast cancer patients
May 3, 2007

Researchers from Erasmus Cancer Center validate the clinical and prognostic utility of the HOXB13/IL17BR ratio in breast cancer patients
February 26, 2007